Authors' recommendations: Sarcoidosis is an inflammatory multisystem disorder of unknown etiology that is characterized by the development of noncaseating granulomas (collections of immune cells and other cells) in one or more organ systems. The incidence peaks between the second and third decades of life, with another peak occurring in women between the fourth and sixth decades. In the United States, the incidence among Caucasians ranges from 10 to 14 cases per 100,000 persons, and for African Americans, from 36 to 64 cases per 100,000 persons. The prevalence in Europe is estimated at 40 cases per 100,000 persons. Neurosarcoidosis is a manifestation of sarcoidosis in the central nervous system (CNS), and is characterized by inflammation and abnormal cells within the CNS. Lesions due to neurosarcoidosis can occur both within the brain parenchyma and the meninges, resulting in a variety of clinical symptoms. This specific disorder is involved in approximately 5% to 26% of patients with systemic sarcoidosis. No standardized treatment regimens for sarcoidosis have been established. Typical first-line treatment includes high-dose corticosteroids, although cumulative adverse effects and relative contraindications render long-term use of this treatment problematic. Hence, there is growing interest in alternative treatment options for sarcoidosis and neurosarcoidosis.

Project Status: Completed

Year Published: 2011

URL for published report: http://www.hayesinc.com/hayes/crd/?crd=13046

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2011 Winifred S. Hayes, Inc